<SEC-DOCUMENT>0001004878-17-000204.txt : 20170831
<SEC-HEADER>0001004878-17-000204.hdr.sgml : 20170831
<ACCEPTANCE-DATETIME>20170831173043
ACCESSION NUMBER:		0001004878-17-000204
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20170831
DATE AS OF CHANGE:		20170831

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-205444
		FILM NUMBER:		171064044

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prospsuppddee8-17.txt
<DESCRIPTION>PRO SUPP SERIES DD & EE WARRANTS
<TEXT>
PROSPECTUS SUPPLEMENT                           Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplement                            Registration No. 333-205444
 dated December 8, 2016)



                               CEL-SCI CORPORATION
                        Series DD and Series EE Warrants



On August 29, 2017 the Company extended the expiration date of its Series DD and
Series EE warrants  until the close of business on December 1, 2017.  The Series
DD and Series EE  warrants  were  issued as part of a  financing  on December 8,
2016.  As a  result  of the  reverse  stock  split  approved  by  the  Company's
shareholders and adopted by the Company's directors:

     o    the  holders  of the  Series DD  warrants  are  entitled  to  purchase
          1,360,960 shares of the Company's common stock at an exercise price of
          $4.50 per share; and

     o    the  holders  of the  Series EE  warrants  are  entitled  to  purchase
          1,360,960 shares of the Company's common stock at an exercise price of
          $4.50 per share.





























                   Prospectus Supplement dated August 29, 2017

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
